scholarly journals Potential for all-trans retinoic acid [tretinoin] to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma, and renal cell carcinoma

2008 ◽  
Vol 7 (10) ◽  
pp. 1515-1519 ◽  
Author(s):  
R.E. Kast
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Cell Carcinoma ◽  
Treatment Response ◽  
Chronic Myelogenous Leukemia ◽  
Interferon Alpha ◽  
Renal Cell ◽  
Myelogenous Leukemia ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

Phase II Study of Interferon-?? and All-Trans Retinoic Acid in Metastatic Renal Cell Carcinoma

1998 ◽  
Vol 21 (1) ◽  
pp. 62-64 ◽  
Author(s):  
Bernard Escudier ◽  
Alain Ravaud, ◽  
Dominique Berton ◽  
Christine Chevreau ◽  
Jean-Yves Douillard ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

Phase I trial of interferon ?2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma

Cancer ◽  
2002 ◽  
Vol 95 (6) ◽  
pp. 1220-1227 ◽  
Author(s):  
Jonathan S. Goldberg ◽  
Manuel Vargas ◽  
Alyssa S. Rosmarin ◽  
Matthew I. Milowsky ◽  
Nicholas Papanicoloau ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Trial ◽  
Advanced Renal Cell Carcinoma ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

Phase 1/2 Clinical Trial of Interferon ??2b and Weekly Liposome-encapsulated All-trans Retinoic Acid in Patients With Advanced Renal Cell Carcinoma

2007 ◽  
Vol 30 (6) ◽  
pp. 655-662 ◽  
Author(s):  
Stephen A. Boorjian ◽  
Matthew I. Milowsky ◽  
Jodi Kaplan ◽  
Martin Albert ◽  
Marta Vallee Cobham ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase 1 ◽  
Advanced Renal Cell Carcinoma ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

Clinical and in vitro Response to 13-cis-Retinoic Acid in Interferon-alpha Resistant Renal Cell Carcinoma

1997 ◽  
Vol 12 (3) ◽  
pp. 143-147 ◽  
Author(s):  
Jan Buer ◽  
Michael Probst ◽  
Stefan Duensing ◽  
Harald Köditz ◽  
Anke Franzke ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Renal Cell ◽  
In Vitro Response

Treatment of concurrent metastatic renal cell carcinoma and chronic myelogenous leukemia – easier said than done? A case report

2010 ◽  
Vol 17 (4) ◽  
pp. 436-439 ◽  
Author(s):  
Fouad Al-Najjar ◽  
Anthony Jarkowski
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Side Effects ◽  
Cell Carcinoma ◽  
Chronic Myelogenous Leukemia ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Myelogenous Leukemia ◽  
Treatment Regimens ◽  
Treatment Side Effects

Treating two active malignancies concurrently can be exceedingly difficult. Complications can occur from the different treatment regimens, especially if they share common targets, and the progressing diseases can make managing treatment side-effects even more challenging. We report a case of a patient with coexisting CML and mRCC who progressed on multiple lines of mRCC therapy while experiencing significant dose limiting side-effects.

Low Activity of 13-cis-Retinoic Acid Plus Interferon Alpha 2a in Advanced Renal Cell Carcinoma

2002 ◽  
Vol 25 (2) ◽  
pp. 123-125 ◽  
Author(s):  
Alejandro V. Jaremtchuk ◽  
Enrique F. Aman ◽  
Walter Ponce ◽  
Juan José Zarbá ◽  
Alejandro M. Ferro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Low Activity

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.

1998 ◽  
Vol 16 (5) ◽  
pp. 1820-1825 ◽  
Author(s):  
W M Stadler ◽  
T Kuzel ◽  
M Dumas ◽  
N J Vogelzang
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Cell Carcinoma ◽  
Median Survival ◽  
Interferon Alpha ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Performance Status ◽  
Interleukin 2 ◽  
Minor Response

PURPOSE To determine the response rate and toxicity of oral 13-cis-retinoic acid (CRA) added to an outpatient regimen of subcutaneous interleukin-2 (IL2) and interferon-alpha (IFNA) in previously untreated patients with metastatic renal-cell carcinoma (RCC). PATIENTS AND METHODS Eligibility included a performance status of 2 or better, no significant end-organ dysfunction, and written informed consent. Characteristics of 47 of 48 assessable patients included a median performance status of 0, prior nephrectomy in 68% of patients, one metastatic site in 30% of patients, and lung-only metastatic disease in 21% of patients. Therapy consisted of IL2 11 x 10(6) IU 4 days per week for 4 weeks, IFNA 9 x 10(6) IU 2 days per week for 4 weeks, and CRA 1 mg/kg daily on a 6-week cycle. RESULTS Eight of 47 patients (17%) responded (one complete response, seven partial responses). Three partial responders were rendered disease free by subsequent surgical resection. Four additional patients experienced a minor response in lung or soft tissue metastases. The median duration of response, which included minor responses, was 42 weeks, and median survival was 74 weeks (17 months). Grades 3 or greater toxicities during the first cycle included flu-like symptoms (21% of patients), fatigue (6% of patients), and nausea and vomiting (15% of patients). Significant cumulative toxicities were hyperlipidemia (four of 18 patients), and cardiomyopathy (one of 18 patients). There was one therapy-related death. CONCLUSION Outpatient CRA plus IL2 and IFNA is feasible and modestly effective in metastatic RCC. The prolonged median survival is encouraging, but randomized trials are required to show that the combination represents an improvement over single-agent immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document